

This Patient Group Direction (PGD) must only be used by registered healthcare professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

PATIENT GROUP DIRECTION (PGD)

Supply of doxycycline for the treatment of uncomplicated *Chlamydia trachomatis*.

For the supply of **Doxycycline 100mg on Patient Group Direction (PGD)** by **community pharmacists working within the boundaries of Brighton & Hove City Council (BHCC)** and contracted to provide treatment for **chlamydia trachomatis infection** as part of the locally commissioned Sexual Health and Contraceptive Service.

Please note – the BHCC Sexual Health and Contraception service does not include the treatment of uncomplicated *Mycoplasma genitalium* infection, non-gonococcal or non-specific urethritis (NGU, NSU) and therefore they have been removed from the inclusion criteria. Guidance pertaining to the management of these conditions has also been removed.

Version Number 2.1

Change History	
Version and Date	Change details
Version 1 April 2020	New template
Version 1.1 May 2020	Minor reordering (content unchanged)
Version 1.2 October 2020	<p>Removed from criteria for inclusion: Clinical epididymo-orchitis (where the practitioner is competent in management of men with testicular pain) and individuals who present with clear penile discharge where there is no access to microscopy facilities to diagnose NSU/NGU.</p> <p>Advisory wording added to inclusion criteria section: NOTE – all criteria for inclusion within the BASHH approved national PGD templates for sexual health are based on diagnostic management in line with BASHH guidance. Where services do</p>

Reference Number: BH2018 13
 Valid from: 1st April 2025
 Review date: September 2025
 Expiry date: March 2026

	not have access to diagnostics and treatment is syndromic then the PGD template will need to be locally adapted to reflect local practice being mindful of the BASHH guidance.
Minor amendments May 2021	Correction of spelling in interactions section – acretin amended to acitretin Exclusion criteria - Glucose galactose intolerance amended to Glucose galactose malabsorption Removed from Clinical condition or situation to which this PGD applies and PGD title - clinical epididymo-orchitis
Version 2.0 April 2023	Updated template due to expiry – no significant changes to clinical content.
Version 2.1 July 2023	Updated exclusion criteria – removed “Sucrose or fructose intolerance, glucose galactose malabsorption, sucrose-isomaltase insufficiency”. Removed any reference to treatment of epididymo-orchitis.

PGD DEVELOPMENT GROUP

Date PGD template comes into effect:	April 2023
Review date	September 2025
Expiry date:	March 2026

This PGD template has been peer reviewed by the Reproductive Health PGDs Short Life Working Group in accordance with their Terms of Reference. It has been approved by British Association for Sexual Health and HIV (BASHH)/BASHH Bacterial Special Interest Group (BSIG) in January 2023.




This section MUST REMAIN when a PGD is adopted by an organisation.

Name	Designation
Ali Grant	Highly Specialist Clinical Pharmacist: HIV, Sexual and Reproductive Health
Alison Crompton	Community pharmacy
Andrea Smith	Community pharmacy
Carmel Lloyd	Royal College of Midwives
Chetna Parmar	Pharmacist adviser, Umbrella
Clare Livingstone	Royal College of Midwives
Deborah Redknapp	English HIV and Sexual Health Commissioners Group (EHSCHG)
Dipti Patel	Local authority pharmacist
Dr Achyuta Nori	Consultant in Sexual Health and HIV
Dr Cindy Farmer	Vice President, General Training Faculty of Sexual and Reproductive Healthcare (FSRH)
Dr John Saunders	Consultant in Sexual Health and HIV
Dr Kathy French	Pan London PGD working group
Dr Rachael Jones	Consultant in HIV and Sexual Health, Chelsea and Westminster NHS Foundation Trust
Dr Rita Browne	Consultant in Sexual Health and HIV
Dr Sarah Pillai	Associate Specialist Sexual Health
Emma Anderson	Centre for Pharmacy Postgraduate Education (CPPE)
Heather Randle	Royal College of Nursing

Reference Number: BH2018 13
Valid from: 1st April 2025
Review date: September 2025
Expiry date: March 2026

Jo Jenkins (Working Group Co-ordinator to Version 2.0)	Lead Pharmacist PGDs and Medicine Mechanisms, SPS
Jodie Crossman	Specialist Nurse. BASHH SHAN SIG Chair
Belinda Loftus	Specialist Nurse, BASHH Board Nurse Representative, BASHH SHAN SIG Secretary
Portia Jackson	Pharmacist, Cambridgeshire Community Services
Sally Hogan	British Pregnancy Advisory Service (BPAS)
Sandra Wolper	Associate Director Specialist Pharmacy Service
Tracy Rogers	Director Specialist Pharmacy Service
Rosie Furner (Working Group Co-ordinator from Version 2.1)	Specialist Pharmacist PGDs and Medicine Mechanisms, SPS

ORGANISATIONAL AUTHORISATIONS

Name	Job title and organisation	Signature	Date
Senior doctor	Dr Deborah Williams Consultant HIV/Sexual Health University Hospitals Sussex		13/2/25
Senior pharmacist	Janet Rittman Pharmaceutical Advisor Brighton & Hove City Council		15/1/25
Person signing on behalf of authorising body	Caroline Vass Director of Public health Brighton & Hove City Council		25/03/25

1. Characteristics of staff	
Qualifications and professional registration	Current contract of employment within a Local Authority or NHS commissioned service or an NHS Trust/organisation. Registered healthcare professional listed in the legislation as able to practice under Patient Group Directions.
Initial training	<p>The registered healthcare professional authorised to operate under this PGD must have undertaken appropriate education and training and successfully completed the competencies to undertake clinical assessment of patient leading to diagnosis of the conditions listed.</p> <p>The Brighton and Hove Sexual Health and Contraception Service Specification details the training and accreditation requirements for Community Pharmacists and Pharmacy Technicians.</p> <p>Specifics of the training include:</p> <ul style="list-style-type: none"> • Completion of the Chlamydia Testing and Treatment Service Declaration of Competence (DoC) on the Centre for Pharmacy Postgraduate Education (CPPE) website. https://www.cppe.ac.uk/services/declaration-of-competence Pharmacists/ pharmacy technicians personalised statement of declaration should be retained, which may need to be provided to commissioners and/or employers when required via the CPPE Viewer. • Completion of the mandatory Health Education England Safeguarding Children level 2 and Safeguarding Adults level 2 e-learning for healthcare (this can be accessed through the CPPE website) and passed the associated level 2 assessment within the last 2 years. • To review the local safeguarding policies and contact information. Information is available from the following links https://www.bhscp.org.uk https://www.bhsab.org.uk • To review the local policies and documentation for this service and references associated with this PGD. • To complete continuing professional development as defined by the General Pharmaceutical Council (GPhC) and take part in an audit as detailed in the service specification.

Competency assessment	<ul style="list-style-type: none"> Individuals operating under this PGD must be assessed as competent (see Appendix A) or complete a self-declaration of competence for Chlamydia testing and/or treatment. Staff operating under this PGD are encouraged to review their competency using the NICE Competency Framework for health professionals using patient group directions
Ongoing training and competency	<ul style="list-style-type: none"> Individuals operating under this PGD are personally responsible for ensuring they remain up to date with the use of all medicines and guidance included in the PGD - if any training needs are identified these should be discussed with the senior individual responsible for authorising individuals to act under the PGD and further training provided as required. Organisational PGD and/or medication training as required by employing Trust/organisation.
The decision to supply any medication rests with the individual registered health professional who must abide by the PGD and any associated organisational policies.	

1. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	<ul style="list-style-type: none"> Genital, pharyngeal and/or rectal <i>Chlamydia trachomatis</i> infection evidenced by contact slip, text message or other written confirmation from the Chlamydia Screening Programme (CSP) Asymptomatic individuals presenting within 2 weeks of sexual contact with an individual with a confirmed diagnosis of any of the conditions detailed below.
Criteria for inclusion	<ul style="list-style-type: none"> Individuals with a positive test for <i>Chlamydia trachomatis</i> infection in the genitals, rectum or pharynx. Asymptomatic individuals presenting within 2 weeks of sexual contact with an individual with a confirmed diagnosis of chlamydia, who are unwilling/unable to defer testing after the 2-week window period. A single repeat treatment course for individuals who have had sexual intercourse within 7 days of receiving treatment or who have had sex with partner untreated for the above condition. Consent given. Aged 13 years and over. All individual under the age of 19 years - follow local young person's risk assessment and safeguarding information bhscp.org.uk.

<p>Criteria for exclusion</p>	<ul style="list-style-type: none"> • Consent not given. • Individuals under 13 years of age. • Individuals under 16 years old and assessed as lacking capacity to consent using the Fraser Guidelines. • Individuals 16 years of age and over and assessed as lacking capacity to consent. <p>Medical history</p> <ul style="list-style-type: none"> • Individuals with clinical proctitis or PID • Individuals with confirmed Lymphogranuloma venereum (LGV) or a contact of LGV. • Breast feeding • Known pregnancy • Known hepatic impairment • Presence of concomitant conjunctivitis and/or joint pain/swelling • Acute porphyria • Myasthenia gravis • Systemic Lupus Erythematosus (SLE) • Individuals with oesophagitis and oesophageal ulcerations. <p>Medication history</p> <ul style="list-style-type: none"> • Any concurrent interacting medicine(s) – see Section 4 Drug interactions • Known allergy or hypersensitivity to doxycycline, other tetracycline antibiotics or to any component of the product - see Summary of Product Characteristics (SPC)
<p>Cautions including any relevant action to be taken</p>	<ul style="list-style-type: none"> • If the individual is less than 16 years of age an assessment based on Fraser guidelines must be made and documented. • Individuals taking the following medication should be advised that additional monitoring is required – advise individual to contact service who prescribe/monitor the affected medications: <ul style="list-style-type: none"> ○ ciclosporin – monitoring of ciclosporin levels may be indicated ○ phenindione – INR monitoring advised ○ warfarin – INR monitoring advised • Discuss with appropriate medical/independent non-medical prescriber any medical condition or medication of which the healthcare professional is unsure or uncertain.
<p>Action to be taken if the individual is excluded or declines treatment</p>	<ul style="list-style-type: none"> • If the presenting individual is under 13 years of age the healthcare professional should speak to the local safeguarding lead and follow the local safeguarding policy (note under 13 years of age excluded from treatment under this PGD).

	<ul style="list-style-type: none"> • If declined ensure individual is aware of the need for treatment and the potential consequences of not receiving treatment. • Explain the reasons for exclusion to the individual and document in the consultation record. • Record reason for decline in the consultation record. • Where required refer the individual to a suitable health service provider if appropriate and/or provide them with information about further options.
--	--

2. Description of treatment

Name, strength & formulation of drug	Doxycycline 50mg or 100mg capsules or 100mg dispersible tablets.
Legal category	POM
Route of administration	Oral
Off label use	<p>Medicines should be stored according to the conditions detailed in the Storage section below. However, in the event of an inadvertent or unavoidable deviation of these conditions the local pharmacy or Medicines Management team must be consulted. Where medicines have been assessed by pharmacy/Medicines Management in accordance with national or specific product recommendations as appropriate for continued use this would constitute off-label administration under this PGD. The responsibility for the decision to release the affected drugs for use lies with pharmacy/Medicines Management.</p> <p>Where a medicine is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the drug is being offered in accordance with national guidance but that this is outside the product licence.</p>
Dose and frequency of administration	100mg twice daily
Duration of treatment	7 days
Quantity to be supplied	7 day supply - appropriately labelled pack/s to a total quantity of 28x50mg, 14x100mg capsules or 14x100mg dispersible tablets.
Storage	Medicines must be stored securely according to national guidelines and in accordance with the product SPC.
Drug interactions	<p>All concurrent medications should be reviewed for interactions.</p> <p>The interactions listed as severe/concurrent use to be avoided in the BNF are:</p> <ul style="list-style-type: none"> • Acenocoumarol • Acitretin

	<ul style="list-style-type: none"> • Alitretinoin • Isotretinoin • Lithium • Tretinoin <p>A detailed list of all drug interactions is available in the BNF or the product SPC</p>
<p>Identification & management of adverse reactions</p>	<p>A detailed list of adverse reactions is available in the SPC and BNF</p> <p>The following side effects are reported as common in the doxycycline SPC but note this list may not reflect all reported side effects:</p> <ul style="list-style-type: none"> • Hypersensitivity reactions • Headache • Nausea • Vomiting • Photosensitivity skin reactions • Rash including maculopapular, erythematous rashes and Henoch-Schonlein purpura • Urticaria • Hypotension • Pericarditis • Tachycardia • Dyspnoea • Peripheral oedema
<p>Management of and reporting procedure for adverse reactions</p>	<ul style="list-style-type: none"> • Healthcare professionals and patients/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme • Record all adverse drug reactions (ADRs) in the patient's medical record. • Report via organisation incident policy.
<p>Written information and further advice to be given to individual</p>	<p>Medication:</p> <ul style="list-style-type: none"> • Give patient information leaflet (PIL) provided with the original pack. Explain mode of action, side effects, and benefits of the medicine • Advise to swallow the capsules whole with plenty of fluids during meals while sitting or standing and well before bedtime to prevent irritation to the oesophagus. • Advise not to take antacids or preparations containing calcium, iron, zinc and magnesium salts at the same time as doxycycline, including those medications purchased. • Advise to avoid exposure to direct sunlight or ultraviolet light. <p>Condition:</p> <ul style="list-style-type: none"> • Verbal and written information on <i>Chlamydia trachomatis</i>

	<ul style="list-style-type: none"> • Discuss implications of incompletely treated/untreated infection of self or partner. • Advise to abstain completely from sexual intercourse (even with condoms) including oral sex, during treatment and until treatment course completed and until partner(s) treatment completed. Where not achievable advise on use of condoms. • Discuss risk of re-infection, and further transmission of infection, if after treatment sexual intercourse takes place with an untreated partner/s • Discuss partner/s notification and issue contact slips if appropriate • Offer condoms and advice on safer sex practices and possible need for screening for sexually transmitted infections (STIs) • Where treatment not supplied via a sexual health clinic ensure the individual has contact details of local sexual health services.
Follow up treatment	<ul style="list-style-type: none"> • The individual should be advised to seek medical advice in the event of an adverse reaction. • Follow local protocol for Chlamydia follow up and partner notification. • Individuals who have not had a full STI screen (or who did not have Chlamydia diagnosed in a sexual health clinic) should be advised to attend an appropriate service for a full STI screen. • Routine follow-up/TOC for uncomplicated Chlamydia following treatment with doxycycline is unnecessary, except in the following situations where local protocols should be followed: <ul style="list-style-type: none"> ○ Where poor compliance is suspected ○ Where symptoms persist ○ Rectal infections ○ Under 25 year olds <p>Individuals should be referred to SHAC https://brightonsexualhealth.com for follow up.</p>
Records	<p>Record:</p> <ul style="list-style-type: none"> • The consent of the individual and <ul style="list-style-type: none"> ○ If individual is under 13 years of age record action taken ○ If individual is under 16 years of age document capacity using Fraser guidelines. If not competent record action taken. ○ If individual over 16 years of age and not competent, record action taken • If individual not treated under PGD record action taken • Name of individual, address, date of birth • GP contact details where appropriate • Relevant past and present medical and sexual history,

	<p>including medication history.</p> <ul style="list-style-type: none"> • Examination or microbiology finding/s where relevant. • Any known allergies and nature of reaction • Name of registered health professional • Name of medication supplied • Date of supply • Dose supplied • Quantity supplied including batch number and expiry date • Advice given about the medication including side effects, benefits, and when and what to do if any concerns • Advice given, including advice given if excluded or declines treatment • Details of any adverse drug reactions and actions taken • Any referral arrangements made • Any supply outside the terms of the product marketing authorisation • Recorded that supplied via Patient Group Direction (PGD) <p>Records should be signed and dated (or a password controlled e-records) and securely kept for a defined period in line with local policy.</p> <p>All records should be clear, legible and contemporaneous.</p> <p>A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.</p>
--	---

3. Key references

<p>Key references (accessed September 2022)</p>	<ul style="list-style-type: none"> • Electronic Medicines Compendium [accessed June 2023] http://www.medicines.org.uk/ • Electronic BNF https://bnf.nice.org.uk/ • NICE Medicines practice guideline “Patient Group Directions” https://www.nice.org.uk/guidance/mpg2 • BASHH CEG September 2018 – Update on the treatment of <i>Chlamydia trachomatis</i> (CT) infection https://www.bashhguidelines.org/media/1191/update-on-the-treatment-of-chlamydia-trachomatis-infection-final-16-9-18.pdf • BASHH UK National Guideline on the management of non-gonococcal urethritis www.bashhguidelines.org/media/1051/ngu-2015.pdf; • British Association for Sexual Health and HIV national guideline for the management of infection with <i>Mycoplasma genitalium</i> Mycoplasma Genitalium 2018
--	--

	<p><u>BASHH</u></p> <ul style="list-style-type: none">• Royal Pharmaceutical Society Safe and Secure Handling of Medicines December 2018 <u>https://www.rpharms.com/recognition/setting-professional-standards/safe-and-secure-handling-of-medicines</u>
--	---

**Appendix A –Registered health professional authorisation sheet
(Pharmacist/Pharmacy Technician)**

PGD Name/Version Supply of doxycycline for the treatment of uncomplicated Chlamydia trachomatis.

Valid from: 1st April 2025

Expiry: March 2026

Before signing this PGD, check that the document has had the necessary authorisations. Without these, this PGD is not lawfully valid.

Registered health professional

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation (Pharmacist/Pharmacy technician)	Signature	Date

Authorising manager

I confirm that the registered health professionals named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of			
..... for the above named health care professionals who have signed the PGD to work under it.			
Name	Designation	Signature	Date

Note to authorising manager

Please add the name of the organisation above.

Score through unused rows in the list of registered health professionals to prevent additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those registered health professionals authorised to work under this PGD.

Records

A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with BHCC service contract and specification.

- For adults all PGD documentation in a patient's clinical record must be kept for 8 years after the last entry.
- For children all PGD documentation in a patient's clinical record must be kept until the child is 25 years old or for 8 years after a child's death.